Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404327 | 0.91 | UCHL1 (0.46) | UCHL1HIF1AFAAHMAPTADORA1 | |
| SCHEMBL21458253 | 0.89 | UCHL1 (0.44) | UCHL1NPBWR1FAAH | |
| SCHEMBL12456444 | 0.88 | UCHL1 (0.45) | UCHL1NPBWR1BRD4FAAHMAPK1 | |
| SCHEMBL24784632 | 0.82 | UCHL1 (0.41) | UCHL1SNCA | |
| SCHEMBL30018541 | 0.82 | UCHL1 (0.41) | UCHL1SNCA | |
| SCHEMBL1079965 | 0.81 | UCHL1 (0.35) | UCHL1 | |
| SCHEMBL759935 | 0.80 | NPBWR1 (0.44) | UCHL1NPBWR1BRD4MCHR1PKM | |
| SCHEMBL760501 | 0.79 | UCHL1 (0.45) | UCHL1HIF1ASNCACACNA1H | |
| SCHEMBL31357429 | 0.78 | UCHL1 (0.53) | UCHL1NPBWR1BRD4SNCAMCHR1 | |
| SCHEMBL24996627 | 0.78 | UCHL1 (0.53) | UCHL1NPBWR1BRD4SNCAMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | UCHL1 4282/4885NPBWR1 4290/4885HIF1A 2537/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | UCHL1 4282/4885NPBWR1 4290/4885HIF1A 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.